Table I.

Questionnaire sent to participants of the Mirasol^® haemovigilance programme.

Name of Institution, Department:
Period of report:
Blood component	Platelets		Plasma
	Apheresis	Whole blood	Apheresis	Whole blood
Total produced
Total Mirasol®-treated
Total issued to hospitals
Total Mirasol® products issued to hospitals
Total expired Mirasol® products
Total transfused Mirasol® products
Total n. of patients transfused with the products
Total n. of adverse event reports, with grades of severity (I, II, III, IV)
N. of adverse events reports for Mirasol®-treated products, with grades of severity (I, II, III, IV)
Imputability levels: definite, probable, unlikely, excluded
Patient’s disease
Previous history of transfusion (yes/no)
Presence of allo-antibodies before transfusion (yes/no)